Skip to main content
NNDM
NASDAQ Manufacturing

Nano Dimension's $890M Infinite Epigenetics Deal Stalls as Exclusivity Expires

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Computer Hardware Stocks · Technology
Sentiment info
Negative
Importance info
7
Price
$1.59
Mkt Cap
$334.837M
52W Low
$1.19
52W High
$2.32
52W Position info
34% above low
Off High info
31% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

NNDM sits 34% above its 52-week low of $1.19 on light trading volume (0.4× avg).

Summary

Nano Dimension's proposed $890 million acquisition of Infinite Epigenetics has stalled after the exclusivity period expired without a definitive agreement. The company also appointed Nadav Kidron to its board.


Key Events · M&A and Partnerships · NNDM

  • Infinite Epigenetics Deal Stalls

    The 30-day exclusivity period under the non-binding term sheet expired on July 15, 2026, and as of August 16, 2026, no definitive agreement has been reached.

  • Strategic Pivot in Limbo

    The $890 million acquisition was central to Nano Dimension's pivot into epigenetics and its defense against activist Murchinson; its stall leaves the company's direction uncertain.

  • New Director Appointed

    Nadav Kidron, CEO of Oramed Pharmaceuticals, was appointed to the board as a Class II director, effective immediately, and will serve on the Audit and Compensation Committees.

  • Next Milestone Unclear

    The filing does not state whether negotiations will continue or if the company will pursue alternative strategies.


Analysis · NNDM · Manufacturing

The non-binding term sheet to acquire Infinite Epigenetics for $890 million has lapsed without a definitive agreement. The 30-day exclusivity period ended July 15, 2026, and as of August 16, 2026, no deal has been reached. This is a material setback for the company's strategic pivot, which was announced in June 2026 and was a central element of its defense against activist investor Murchinson. The appointment of Nadav Kidron, an experienced life sciences executive, to the board may signal a continued focus on the healthcare sector, but the stalled acquisition leaves the company's strategic direction uncertain.

At the time of this filing, NNDM was trading at $1.59 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $334.8M. The 52-week trading range was $1.19 to $2.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NNDM - Latest Insights

NNDM
Aug 06, 2026, 5:56 PM EDT
Filing Type: 10-Q
Importance Score:
8
NNDM
Aug 06, 2026, 4:51 PM EDT
Source: Reuters
Importance Score:
8
NNDM
Jul 27, 2026, 7:06 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
NNDM
Jul 22, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
NNDM
Jul 21, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
9